Incidence of complications after transrectal ultrasonography-guided biopsy of the prostate in a local tertiary institution

Wu M W F, Sevilla E M, Raman L, Consigliere D, Siow W Y, Tiong H Y

ABSTRACT

Introduction: This study aimed to evaluate the risk of complications for patients who received periprostatic nerve block (PPNB) with one percent lignocaine before transrectal ultrasonography (TRUS) biopsy of the prostate.

Methods: From 2008 to 2009, data on 526 consecutive patients who underwent prostate biopsy was prospectively recorded and analysed. 475 (90.3 percent) patients received PPNB with 10 ml of one percent lignocaine (Group 1), which was carried out under TRUS-guidance and prior to biopsy. 51 (9.7 percent) patients received diclofenac (100 mg) intramuscular injections or no analgesia (Group 2). Complications were defined as any adverse effects after biopsy. Serious complications were defined as those requiring hospitalisation or invasive/operative procedures for treatment.

Results: At baseline, both groups were comparable. The mean prostate-specific antigen level in Group 1 was higher than that in Group 2 (48.6 +/- 13.8 versus 19.0 +/- 4.3 ng/ml; p-value is 0.04). There was no perioperative mortality. Post-procedural complications were reported in 23.4 percent (n is 111) of patients in Group 1 and 25.5 percent (n is 13) in Group 2 (p-value is 0.27). Serious complications were reported in 2.5 percent (n is 12) and 7.1 percent (n is 3) of Group 1 and 2 patients (p-value is 0.10), respectively. Both univariable and logistic regression revealed age below 65 years and pre-procedure complaints of lower urinary tract symptoms as independent predictors for complications (p-values are 0.02 and 0.006, respectively).

Conclusion: PPNB with one percent lignocaine is a safe analgesic procedure to perform in patients undergoing TRUS biopsy.

Keywords: complications, periprostatic nerve block, transrectal prostate biopsy

INTRODUCTION

Transrectal ultrasonography (TRUS)-guided biopsy of the prostate is widely regarded as the gold standard for diagnosing prostate cancer. It is usually performed in the outpatient setting, as it is considered a minor and safe procedure. Although it is well tolerated by most men, a considerable number of patients do complain of discomfort and pain. Various studies show that 65%–90% of patients complain of mild discomfort to severe pain. Irani et al reported that up to 19% of patients would not undergo a repeat procedure without any form of anaesthesia.

Periprostatic nerve block (PPNB) was first introduced by Nash et al in 1996 and since then, various prospective clinical studies, including a meta-analysis, have shown that PPNB significantly reduces the pain score in patients when compared to a placebo or other forms of analgesia such as intramuscular injections or rectal administration of non-steroidal anti-inflammatory drugs (NSAIDs) and intrarectal local anaesthesia.

The most common complications after a TRUS biopsy are haematuria, urinary tract infections (UTIs), rectal bleeding and acute retention of urine. Some complications are serious enough to warrant hospitalisation and/or operative procedures for treatment. The rate of serious complications was 0.5%–6.6% in different studies. Recent studies have re-highlighted the emerging significance of TRUS complications as increasing number of biopsies and repeat biopsies are performed in an era of prostate-specific antigen (PSA) screening. Following our initial evaluation and
and the seminal vesicle, as described earlier. The prostate just lateral to the junction between the prostate and the number of cores taken for biopsy also depended on the individual clinician’s decision. All procedures were performed in the above standardised technique on an outpatient basis. All patients were reviewed 2–3 weeks after the procedure, and any complications reported during the visit were recorded in the clinical case notes. Complications that were additionally self-reported by the patients after the biopsy, including unscheduled post-procedure outpatient visits and phone calls to the outpatient clinic, were also captured in the clinical notes. Serious complications were defined as those requiring hospitalisation or interventions, including intravenous antibiotics, cystoscopic procedures or operations for treatment. These were recorded in the same unified outpatient and inpatient records.

Demographic data, PSA value, clinical and US parameters of the prostate, number of cores taken and complications were recorded for each patient in a computerised database by a dedicated database administrator, who reviewed all the clinical records and investigational results of the patients one month after the prostate biopsy. Statistical analysis was performed using the Statistical Package for the Social Sciences version 17 (SPSS, Chicago, IL, USA). Chi-square test was performed for categorical variables, and Student’s t-test and ANOVA were used for analysis of continuous variables. Univariable and multivariable logistic regression were performed to assess the associated risk factors for post-procedural complications. A p-value < 0.05 was considered statistically significant.

RESULTS
At baseline, the two groups were comparable in terms of demographics, clinical and US parameters of the prostate and the number of cores taken for biopsy (Table I). In particular, there were no significant differences in the mean prostate volumes of both groups (44.2 ± 1.0 vs. 45.0 ± 4.0 ml, p = 0.85). However, the mean PSA level in Group 1 was higher than that in Group 2 (48.6 ± 13.8 vs. 19.0 ± 4.3 ng/ml, p = 0.04). Table II shows no statistically significant difference between the two groups in the histological outcomes of the biopsy, with prostate cancer diagnosed in 27.4% (n = 130) of Group 1 and 33.3% (n = 17) of Group 2 patients (p = 0.41).
The total complication rate reported in the two groups was 23.6% (n = 124). Table III shows the demographics and clinical parameters of patients who had complications. The overall complication rate (proportion of patients with at least one complication) was 23.4% (n = 111) in Group 1 patients and 25.5% (n = 13) in Group 2 (p = 0.27). The most commonly reported specific complications in both groups were gross haematuria and UTIs (Table IV). As there were patients who reported more than one specific complication, there was an overlap of patients in the different reported specific complications. The proportion of patients with gross haematuria in Group 2 (n = 9) was significantly higher than that in Group 1 (n = 36) (21.4% vs. 7.6%, p = 0.002). There was no significant difference between the two groups with regard to all other specific complications. No perioperative mortality was noted across the board.

The total serious complication rate (proportion of patients with at least one serious complication) for the two groups was 2.9% (n = 15). Serious complications were reported in 2.5% (n = 12) and 7.1% (n = 3) of Group 1 and 2 patients, respectively (p = 0.104), and only these patients were admitted for treatment. Table IV shows the breakdown of specific serious complications, with some patients having more than one serious specific complication. Due to the small number of patients in both groups, statistical comparison between the specific serious complications was not performed.
Clinical, US and demographic risk factors were analysed for their association with overall complications using both univariable and multivariable models, as shown in Tables V and VI. The mean age group of patients who had complications was significantly lower than those without complications (63.8 ± 9.4 vs. 66.2 ± 8.3 years, p = 0.01), although the difference was clinically small. On univariable analysis, age < 65 years (p = 0.03, odds ratio [OR] 1.56, 95% confidence level [CI] 1.04–2.40) and pre-procedure complaints of lower urinary tract symptoms (LUTS) (p = 0.009, OR 1.73, 95% CI 1.64–2.62) were significantly associated with overall complications. Multivariable logistic regression using these two factors in combination with PPNB confirmed age < 65 years and pre-procedure complaints of LUTS as independent predictors for overall complications (p = 0.02, OR 1.67, 95% CI 1.09–2.54 and p = 0.006, OR 1.80, 95% CI 1.18–2.74, respectively). The number of patients with serious complications was too small for meaningful analysis with the univariable and multivariable models.

**Discussion**

Several studies have already shown that PPNB reduces pain from TRUS prostate biopsy.\(^4\)–\(^6\) Our previous study has ascertained that the pain score was lower in the PPNB group (diclofenac 3.70 ± 2.36 and PPNB 2.24 ± 1.63).\(^6\) In our current population, the mean pain score for patients in the PPNB group (Group 1) was 1.16 ± 0.420 and that for Group 2 was 1.46 ± 0.636 (p = 0.004). Pain score was measured using the Wong-Baker FACES Pain Rating Scale, and none of the patients in this study had pain score > 3. The use of PPNB as an analgesia will become more widespread, since it is a relatively easy and quick procedure to perform just prior to biopsy. With this effective form of analgesia, patients would find TRUS
biopsy to be more acceptable, especially when a repeat biopsy or a higher number of cores is required for a more accurate diagnosis. In this prospective follow-up study, we have shown that the risk of overall complications and serious complications was not significantly increased following the introduction of PPNB into our clinical practice compared to intramuscular injection of diclofenac or no analgesia.

The predictable course and the close proximity of the prostatic neurovascular bundles to the rectal wall mean that they can be easily targeted and accessed by a US-guided needle for the injection of a local anaesthetic. However, there have been reported concerns that the injection of a local anaesthesia may increase bacteriuria and that more needle passes may cause greater rectal bleeding, both of which are already common in TRUS biopsies. Although there are many published studies on the efficacy of PPNB in relieving pain from TRUS prostate biopsy, few other publications have specifically addressed complications from PPNB. The overall and serious complication rates of 23.6% and 2.9%, respectively, from this series are comparable to those reported in other studies. With regard to PPNB, our finding of no increased overall complications is consistent with that of two other published reports. Obek et al studied 100 patients who underwent TRUS biopsy with PPNB as analgesia in a prospective randomised trial, and concluded that there was no increased risk of urethral bleeding. In a paper by Turgut et al, adverse effects associated with PPNB were reported to be mainly pain secondary to the needle puncture, lignocaine-associated problems and radiological changes in the prostate post biopsy. Only 1.5% of the 200 patients experienced post-procedure urinary incontinence; they also concluded that PPNB is a safe and effective analgesia for patients undergoing TRUS biopsy.

No significant difference in specific complications (UTIs or rectal bleeding) between the PPNB and non-PPNB groups was found. Interestingly, the proportion of patients reporting gross haematuria in the non-PPNB (Group 2) was significantly higher when compared to that in Group 1 (21.4% vs. 7.6%), although the proportions of patients on antiplatelet or anticoagulation medications were equivalent between the two groups. The reason for this is unclear, as injections of the neurovascular bundles are relatively distant from the urethra. We do not routinely administer apical lignocaine injections to the prostate. However, the vast majority of cases with haematuria are self-resolving with conservative treatment and do not have serious implications. Maan et al reported no statistically significant difference in the incidence of haematuria or overall bleeding in patients who continued taking aspirin before and after the procedure, and concluded that aspirin does not have to be discontinued before the biopsy. Despite this finding, all our patients who were on antiplatelet or anticoagulation medications were advised to discontinue them before biopsy, and this was confirmed before biopsy was performed.

When univariable and multivariable logistic regressions were performed, younger age and the presence of LUTS were found to be independent predictors for complications. In particular, age < 65 years was found to be significantly predictive of reported overall complications. However, the clinical difference may actually be smaller, as the mean ages of those who had complications and those without were close (63.8 ± 9.4 vs. 66.2 ± 8.3 years, p = 0.010). One possible reason may be that younger patients are more likely to self-report complications compared to older patients.

The presence of LUTS was an independent predictor of complications. The odds of patients with LUTS developing complications after prostate biopsy was 1.80 (95% CI 1.2–2.7) compared to patients who denied any LUTS, i.e. the ‘true’ PSA-screened patients. Hence, patients who undergo PSA screening probably are at a low risk of complications from TRUS biopsy. Therefore, with the pain issues addressed by PPNB, TRUS biopsy can become a truly acceptable follow-up investigation for patients identified by PSA screening.

Although the mean PSA level of the PPBN group was higher (48.6 ± 13.8 vs. 19.0 ± 4.3, p = 0.04) compared to the group without PPNB, the complication rate between the two groups is not significantly different. A higher PSA value can be attributed to either a larger prostate volume, the presence of prostate cancer or prostatitis, and this could translate to greater risk for complications; however, in our study, this was not evident.

### Table VI. Multivariable analysis of risk factors for overall complications.

<table>
<thead>
<tr>
<th>Variable</th>
<th>OR; 95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 65</td>
<td>1.67; 1.09–2.54</td>
<td>0.02</td>
</tr>
<tr>
<td>&gt; 65</td>
<td>0.60; 0.39–0.91</td>
<td></td>
</tr>
<tr>
<td>LUTS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1.80; 1.18–2.74</td>
<td>0.006</td>
</tr>
<tr>
<td>No</td>
<td>0.56; 0.37–0.85</td>
<td></td>
</tr>
<tr>
<td>Administration of PPNB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>1.55; 0.76–3.15</td>
<td>0.23</td>
</tr>
<tr>
<td>No</td>
<td>0.65; 0.32–1.31</td>
<td></td>
</tr>
</tbody>
</table>

OR: odds ratio; CI: confidence interval; LUTS: lower urinary tract symptoms; PPNB: periprostatic nerve block
Despite the link between complications and LUTS, TRUS prostate volume was not a significant predictor of complications, and there was no significant difference in the mean prostate volume between patients with and without complications (45.2 ± 21.5 vs. 43.9 ± 21.6 ml, respectively, p = 0.58). There is evidence to suggest that prostate volume is not the best indicator of bladder outlet obstruction, but other parameters, such as degree of intravesical prostatic protrusion are more predictive of bladder outlet obstruction and LUTS. This is currently the subject of our ongoing research.(16,17)

We acknowledge that there is a lack of randomisation in the study. The administration of PPNB did not allow for blinding. The number of patients in Group 1 (n = 475) was significantly higher, as we have adopted PPNB as the standard of care for TRUS biopsy in our institution. Hence, most patients would be offered this method of pain relief. However, we believe our results reflect the real-life clinical practice of introducing PPNB into clinical urological outpatients, with careful prospective recording of complications to document the safety of a new procedure. This study reflects the ‘true’ complication rate, with the patient’s and clinician’s choice of PPNB taken into account. In addition, by documenting both self-reported complications and serious complications, we believe that a complete picture of morbidity arising from PPNB and TRUS biopsy has been represented. This is important with the increasing attention given to post-biopsy complications, against the background of likely increasing advocates of PSA screening.(18) In conclusion, our study shows that PPNB with 1% lignocaine is a safe analgesic procedure for transrectal ultrasonography-guided biopsy of the prostate evaluated by questionnaire. Urol Oncol 2008; 26:474-8.

REFERENCES